.png){kind=icon}
返回
A
Alberto Zambelli
ASST Papa Giovanni XXIII
46H指数
448论文数
8.5K被引数
收录论文 162
发表时间
.png){kind=icon}
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial在激素受体阳性晚期乳腺癌一线治疗期间，于ESR1突变出现但疾病进展前转换至卡米泽斯特rant（SERENA-6）：一项双盲、安慰剂对照、随机III期试验的扩展分析.png)
Lancet Oncology.png)
Lancet OncologyIF35.9
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2根据肿瘤组织学对激素阳性、HER2阴性晚期乳腺癌患者中一线CDK4/6抑制剂的疗效比较：一项真实世界、多中心、意大利研究PALMARES-2的亚组分析The Breast
OAAI
The BreastIF0
OAAI分享收藏PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]意大利乳腺癌患者预测性BRCA基因检测：意大利科学学会立场文件[意大利医学肿瘤学会(AIOM)；意大利放射治疗与临床肿瘤学会 (AIRO)；意大利全国乳腺外科医师协会 (ANISC)；意大利病理解剖学与诊断细胞学学会 (SIAPeC-IAP)；意大利外科肿瘤学会 (SICO)；意大利人类遗传学会 (SIGU)；意大利全科医学学会 (SIMG)；意大利医学与介入放射学学会 (SIRM)]Cancer Treatment Reviews
Cancer Treatment ReviewsIF10.5
PREAI
分享收藏Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study真实世界中一线帕博西利、瑞博西利或阿贝西利联合内分泌治疗在晚期HR阳性/HER2阴性乳腺癌患者中的疗效比较：多中心PALMARES-2研究的结果Annals of Oncology
Annals of OncologyIF65.4
PREAI
分享收藏